JP2009520503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520503A5 JP2009520503A5 JP2008547621A JP2008547621A JP2009520503A5 JP 2009520503 A5 JP2009520503 A5 JP 2009520503A5 JP 2008547621 A JP2008547621 A JP 2008547621A JP 2008547621 A JP2008547621 A JP 2008547621A JP 2009520503 A5 JP2009520503 A5 JP 2009520503A5
- Authority
- JP
- Japan
- Prior art keywords
- ctla4
- composition
- molecule
- domain
- glycosylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 39
- 230000004988 N-glycosylation Effects 0.000 claims 9
- 230000013595 glycosylation Effects 0.000 claims 9
- 238000006206 glycosylation reaction Methods 0.000 claims 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 6
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 4
- 229920001542 oligosaccharide Polymers 0.000 claims 4
- 150000002482 oligosaccharides Chemical class 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 2
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims 2
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000013628 high molecular weight specie Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000013627 low molecular weight specie Substances 0.000 claims 1
- 238000003468 luciferase reporter gene assay Methods 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75226705P | 2005-12-20 | 2005-12-20 | |
| US75215005P | 2005-12-20 | 2005-12-20 | |
| US60/752,267 | 2005-12-20 | ||
| US60/752,150 | 2005-12-20 | ||
| US84954306P | 2006-10-05 | 2006-10-05 | |
| US60/849,543 | 2006-10-05 | ||
| PCT/US2006/049074 WO2007076032A2 (en) | 2005-12-20 | 2006-12-19 | Compositions and methods for producing a composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009289570A Division JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009520503A JP2009520503A (ja) | 2009-05-28 |
| JP2009520503A5 true JP2009520503A5 (enExample) | 2010-02-18 |
| JP5096369B2 JP5096369B2 (ja) | 2012-12-12 |
Family
ID=38218674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547621A Active JP5096369B2 (ja) | 2005-12-20 | 2006-12-19 | 組成物および組成物の製造方法 |
| JP2009289570A Active JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009289570A Active JP5097194B2 (ja) | 2005-12-20 | 2009-12-21 | 組成物および組成物の製造方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10508144B2 (enExample) |
| EP (2) | EP2253644B1 (enExample) |
| JP (2) | JP5096369B2 (enExample) |
| KR (2) | KR101391457B1 (enExample) |
| CN (1) | CN106589132B (enExample) |
| AU (2) | AU2006330922B2 (enExample) |
| BR (2) | BRPI0620178B1 (enExample) |
| CA (2) | CA2634760C (enExample) |
| CY (1) | CY1114887T1 (enExample) |
| DK (2) | DK1969007T3 (enExample) |
| EA (1) | EA017765B1 (enExample) |
| ES (2) | ES2439641T3 (enExample) |
| HR (1) | HRP20130975T1 (enExample) |
| IL (2) | IL192098A (enExample) |
| MX (1) | MX336807B (enExample) |
| NO (1) | NO20082716L (enExample) |
| NZ (1) | NZ597215A (enExample) |
| PE (1) | PE20080556A1 (enExample) |
| PL (2) | PL2253644T3 (enExample) |
| PT (2) | PT1969007E (enExample) |
| SI (2) | SI1969007T1 (enExample) |
| TW (2) | TWI423986B (enExample) |
| WO (1) | WO2007076032A2 (enExample) |
| ZA (1) | ZA200805301B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| EP2423219B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| CA2717383C (en) | 2008-03-06 | 2017-01-03 | Halozyme, Inc. | Large-scale production of soluble hyaluronidase |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| EP3238749B2 (en) | 2008-10-06 | 2025-06-04 | 3-D Matrix, Ltd. | Tissue plug |
| CN101995476B (zh) * | 2009-08-10 | 2013-07-03 | 中国医学科学院北京协和医院 | 临床化学检验用液体质控血清 |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| WO2011069056A2 (en) | 2009-12-04 | 2011-06-09 | Momenta Pharmaceuticals, Inc. | Antennary fucosylation in glycoproteins from cho cells |
| AU2011214361C1 (en) * | 2010-02-12 | 2016-01-14 | Dpx Holdings B.V. | Single unit antibody purification |
| EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| US20120121574A1 (en) * | 2010-11-15 | 2012-05-17 | Luciano Polonelli | Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore |
| JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
| US8679767B2 (en) * | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| WO2013130604A1 (en) * | 2012-02-27 | 2013-09-06 | Biogen Idec Ma Inc. | High-throughput method for sialic acid quantitation |
| WO2013162951A1 (en) * | 2012-04-22 | 2013-10-31 | Perfinity Biosciences, Inc. | Automated protein digestion, recovery and analysis |
| ES2753150T3 (es) * | 2012-06-29 | 2020-04-07 | Bristol Myers Squibb Co | Métodos para reducir la agregación de glucoproteínas |
| EP3466964A1 (en) * | 2012-07-06 | 2019-04-10 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| EP2855533A4 (en) * | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3628337B1 (en) | 2014-03-10 | 2025-05-28 | 3-D Matrix, Ltd. | Sterilization and filtration of peptide compositions |
| CN117138022A (zh) | 2014-03-10 | 2023-12-01 | 三维矩阵有限责任公司 | 自组装肽组合物 |
| SG11201608848XA (en) | 2014-04-25 | 2016-11-29 | Bristol Myers Squibb Co | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
| US9908932B2 (en) | 2014-10-15 | 2018-03-06 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| RS61943B1 (sr) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Imunomodulatorni proteini sa prilagodljivim afinitetima |
| IL256175B2 (en) | 2015-06-10 | 2024-10-01 | Univ Texas | Using exosomes to treat the disease |
| TWI579030B (zh) * | 2015-12-15 | 2017-04-21 | Ｃｇ生物技術有限公司 | 分離細胞之容器、系統及方法 |
| US10814038B2 (en) | 2016-01-06 | 2020-10-27 | 3-D Matrix, Ltd. | Combination compositions |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| US10613081B2 (en) * | 2016-11-27 | 2020-04-07 | Alireza Palangi | Quality control system and kit for automated ELISA devices |
| WO2018229802A1 (en) * | 2017-06-16 | 2018-12-20 | Ge Healthcare Bio-Sciences Ab | Method for predicting outcome of and modelling of a process in a bioreactor |
| CN109385401A (zh) * | 2017-08-10 | 2019-02-26 | 北京泰德制药股份有限公司 | 一种表达重组蛋白的cho细胞的培养方法 |
| ES2936149T3 (es) * | 2017-09-21 | 2023-03-14 | Codiak Biosciences Inc | Producción de vesículas extracelulares en suspensión unicelular utilizando medios de cultivo de células químicamente definidos |
| WO2019074983A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| JP7432506B2 (ja) | 2017-10-30 | 2024-02-16 | 武田薬品工業株式会社 | 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤 |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| JP7102734B2 (ja) | 2018-01-09 | 2022-07-20 | 東洋製罐グループホールディングス株式会社 | 細胞培養方法及び装置 |
| HUE058711T2 (hu) | 2018-04-20 | 2022-09-28 | Janssen Biotech Inc | Kromatográfiás oszlopos minõség-ellenõrzés anti-IL12/IL23 ellenanyag-készítmények elõállítására szolgáló gyártási eljárásokban |
| CA3106384A1 (en) * | 2018-11-02 | 2020-05-07 | Beijing Vdjbio Co., Ltd. | Modified ctla4 and methods of use thereof |
| US11965900B2 (en) * | 2018-11-09 | 2024-04-23 | Wyatt Technology, Llc | Indicating a status of an analytical instrument on a screen of the analytical instrument |
| US12534492B2 (en) | 2019-06-14 | 2026-01-27 | Agilent Technologies, Inc. | Methods and kits to improve the fluorescent signal of DMB-labeled sialic acids |
| WO2021019295A1 (en) * | 2019-07-26 | 2021-02-04 | Jan Remmereit | Sialic acid for use in the treatment of psoriasis |
| CN110554107B (zh) * | 2019-08-14 | 2022-06-10 | 上海应用技术大学 | 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法 |
| CN114981659A (zh) | 2019-11-21 | 2022-08-30 | 百时美施贵宝公司 | 无标记n-聚糖定量方法 |
| CN111398308B (zh) * | 2020-03-27 | 2023-01-17 | 上海健康医学院 | 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统 |
| JP7415771B2 (ja) | 2020-04-24 | 2024-01-17 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| JP7314859B2 (ja) | 2020-04-30 | 2023-07-26 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2021226551A1 (en) | 2020-05-08 | 2021-11-11 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins and methods of use thereof |
| JP7415783B2 (ja) * | 2020-05-12 | 2024-01-17 | 株式会社島津製作所 | 分析支援装置、分析支援方法および分析支援プログラム |
| US20230313259A1 (en) * | 2020-08-14 | 2023-10-05 | Bristol-Myers Squibb Company | Manufacturing process for protein |
| US20230323422A1 (en) | 2020-08-14 | 2023-10-12 | Bristol-Myers Squibb Company | Method of making protein |
| CN112198302B (zh) * | 2020-10-25 | 2022-12-16 | 中铁二局第一工程有限公司 | 一种细集料含泥量快速检测方法及测量工具 |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| CA3113278C (en) * | 2021-03-25 | 2025-08-12 | Lumex Instruments Canada (0890278 B.C. Ltd.) | Device for electrophoretic analysis of multicomponent liquid samples |
| US20240209060A1 (en) * | 2021-03-31 | 2024-06-27 | Dr. Reddy’S Laboratories Limited | Cell culture process for fusion protein composition |
| CN113241192B (zh) * | 2021-05-18 | 2023-06-20 | 武汉大学中南医院 | 一种证据合成方法和计算机设备 |
| JP7600875B2 (ja) * | 2021-06-01 | 2024-12-17 | 株式会社島津製作所 | 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法 |
| AU2022358612A1 (en) * | 2021-09-28 | 2024-04-11 | Kashiv Biosciences, Llc | An improved process of purification of fusion protein |
| EP4408879A4 (en) * | 2021-09-28 | 2025-08-27 | Kashiv Biosciences Llc | IMPROVED PROCESS FOR PURIFYING FUSION PROTEIN |
| WO2023053030A1 (en) * | 2021-09-28 | 2023-04-06 | Kashiv Biosciences, Llc | An improved process for purification of protein |
| WO2023115027A2 (en) * | 2021-12-16 | 2023-06-22 | Bristol-Myers Squibb Company | Detergent for viral inactivation |
| JP2025016812A (ja) * | 2021-12-16 | 2025-02-05 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
| CA3242953A1 (en) * | 2021-12-17 | 2025-04-29 | Kashiv Biosciences, Llc | IMPROVED METHOD FOR SEPARATION OF LOW MOLECULAR WEIGHT PROTEINS |
| JP2025509749A (ja) * | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| CN116467264B (zh) * | 2023-04-14 | 2025-11-28 | 阿里健康科技(中国)有限公司 | Rf2文件的生成方法、装置、设备和存储介质 |
| US12461955B2 (en) * | 2023-09-08 | 2025-11-04 | Salesforce, Inc. | Integration flow generation using large language models |
| CN117044627B (zh) * | 2023-10-11 | 2023-12-15 | 中国科学院昆明植物研究所 | 一种高山植物塔黄的组培快繁及离体保存方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460694A (en) * | 1981-03-26 | 1984-07-17 | University Of Miami | Bovine glycoproteins and use in diagnosing infectious mononucleosis |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
| US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
| WO1993010260A1 (en) * | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
| WO1995007703A1 (en) * | 1993-09-15 | 1995-03-23 | Alpha Therapeutic Corp. | Alpha1-acid glycoprotein purification process and product |
| US5451660A (en) * | 1993-12-13 | 1995-09-19 | Genentech, Inc. | Method for purifying polypeptides |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| EP0784482A2 (en) | 1994-06-07 | 1997-07-23 | The Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| NZ335207A (en) | 1996-11-15 | 2000-09-29 | Genentech Inc | Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin |
| ES2337091T3 (es) | 1996-11-27 | 2010-04-20 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina. |
| ZA98533B (en) | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030124614A1 (en) | 1997-08-29 | 2003-07-03 | Brighams And Womens Hospital Inc. | Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof |
| ATE309350T1 (de) | 1997-12-03 | 2005-11-15 | Roche Diagnostics Gmbh | Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| EP1084136B1 (en) | 1998-06-01 | 2004-08-25 | Genentech, Inc. | Separation of antibody monomers from its multimers by use of ion-exchange chromatography |
| US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| US6358703B1 (en) * | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| ATE348173T1 (de) | 1999-04-26 | 2007-01-15 | Genentech Inc | Zellenzuchtverfahren für glycoproteine |
| US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| ES2343023T3 (es) * | 2000-03-27 | 2010-07-21 | Genetics Institute, Llc | Procedimientos para purificar proteinas altamente anionicas. |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| PE20011338A1 (es) | 2000-05-26 | 2002-01-13 | Bristol Myers Squibb Co | Moleculas mutantes de ctla4 solubles |
| EP1294391B1 (en) | 2000-06-09 | 2012-08-15 | Bristol-Myers Squibb Company | Combination of agents for inhibiting transplant rejection |
| AU2001272978A1 (en) | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
| US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| SI1935427T1 (en) * | 2000-07-03 | 2018-05-31 | Bristol-Myers Squibb Company | USE OF HEATED CTLA4 MUTANT MOLECULES |
| US6358265B1 (en) | 2000-07-18 | 2002-03-19 | Specialized Health Products, Inc. | Single-step disposable safety lancet apparatus and methods |
| HUP0303930A3 (en) | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| PL204899B1 (pl) | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
| ATE363541T1 (de) * | 2002-03-26 | 2007-06-15 | Lek Tovarna Farmacevtskih | Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen |
| WO2003083066A2 (en) | 2002-03-27 | 2003-10-09 | Immunex Corporation | Methods for increasing polypeptide production |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| AU2003243152A1 (en) | 2002-04-19 | 2003-11-03 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| DK1501369T3 (en) | 2002-04-26 | 2015-09-28 | Genentech Inc | Non-affinity purification of proteins |
| AU2002345524A1 (en) | 2002-06-19 | 2004-01-06 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | A process for the production of substituted phenyl ethers |
| WO2004008100A2 (en) | 2002-07-15 | 2004-01-22 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| US7332303B2 (en) * | 2002-12-23 | 2008-02-19 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
| AU2003300276B2 (en) | 2002-12-23 | 2010-07-01 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| US7118222B2 (en) * | 2003-05-12 | 2006-10-10 | Seiko Epson Corporation | Optical device and protector |
| DE602004029252D1 (de) | 2003-06-13 | 2010-11-04 | Biogen Idec Inc | Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| DE602004026343D1 (de) * | 2003-10-24 | 2010-05-12 | Amgen Inc | Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen |
| BRPI0417916A (pt) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| US8513393B2 (en) | 2006-08-28 | 2013-08-20 | Ares Trading S.A. | Process for the purification of Fc-containing proteins |
| BRPI0716139A2 (pt) | 2006-08-28 | 2013-09-17 | Ares Trading Sa | processo para purificaÇço de proteÍnas de fusço fc |
-
2006
- 2006-12-19 PL PL10153282T patent/PL2253644T3/pl unknown
- 2006-12-19 CA CA2634760A patent/CA2634760C/en active Active
- 2006-12-19 EA EA200801571A patent/EA017765B1/ru not_active IP Right Cessation
- 2006-12-19 CA CA2836123A patent/CA2836123C/en active Active
- 2006-12-19 TW TW101148477A patent/TWI423986B/zh active
- 2006-12-19 DK DK06848052.4T patent/DK1969007T3/da active
- 2006-12-19 JP JP2008547621A patent/JP5096369B2/ja active Active
- 2006-12-19 KR KR1020117029336A patent/KR101391457B1/ko active Active
- 2006-12-19 WO PCT/US2006/049074 patent/WO2007076032A2/en not_active Ceased
- 2006-12-19 AU AU2006330922A patent/AU2006330922B2/en active Active
- 2006-12-19 NZ NZ597215A patent/NZ597215A/xx unknown
- 2006-12-19 EP EP10153282.8A patent/EP2253644B1/en not_active Revoked
- 2006-12-19 PL PL06848052T patent/PL1969007T4/pl unknown
- 2006-12-19 KR KR1020087017540A patent/KR101398713B1/ko active Active
- 2006-12-19 BR BRPI0620178-4A patent/BRPI0620178B1/pt active IP Right Grant
- 2006-12-19 US US12/086,786 patent/US10508144B2/en active Active
- 2006-12-19 ES ES10153282.8T patent/ES2439641T3/es active Active
- 2006-12-19 HR HRP20130975TT patent/HRP20130975T1/hr unknown
- 2006-12-19 PE PE2006001650A patent/PE20080556A1/es not_active Application Discontinuation
- 2006-12-19 CN CN201610350033.8A patent/CN106589132B/zh active Active
- 2006-12-19 TW TW095147641A patent/TWI398520B/zh active
- 2006-12-19 PT PT68480524T patent/PT1969007E/pt unknown
- 2006-12-19 ES ES06848052T patent/ES2433092T3/es active Active
- 2006-12-19 EP EP06848052.4A patent/EP1969007B1/en not_active Revoked
- 2006-12-19 PT PT101532828T patent/PT2253644E/pt unknown
- 2006-12-19 BR BRPI0622251-0A patent/BRPI0622251A2/pt not_active Application Discontinuation
- 2006-12-19 DK DK10153282.8T patent/DK2253644T3/da active
- 2006-12-19 SI SI200631696T patent/SI1969007T1/sl unknown
- 2006-12-19 SI SI200631693T patent/SI2253644T1/sl unknown
-
2008
- 2008-06-12 IL IL192098A patent/IL192098A/en active IP Right Grant
- 2008-06-13 NO NO20082716A patent/NO20082716L/no not_active Application Discontinuation
- 2008-06-18 ZA ZA2008/05301A patent/ZA200805301B/en unknown
- 2008-06-20 MX MX2012006495A patent/MX336807B/es unknown
-
2009
- 2009-12-21 JP JP2009289570A patent/JP5097194B2/ja active Active
-
2010
- 2010-11-08 AU AU2010241289A patent/AU2010241289B2/en active Active
-
2013
- 2013-12-10 IL IL229904A patent/IL229904A0/en unknown
-
2014
- 2014-01-14 CY CY20141100030T patent/CY1114887T1/el unknown
-
2018
- 2018-07-23 US US16/042,977 patent/US10941189B2/en active Active
- 2018-07-24 US US16/044,217 patent/US10808021B2/en active Active
-
2020
- 2020-11-25 US US17/105,358 patent/US12030923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leist et al. | Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. | |
| ES2791333T3 (es) | Anticuerpos anti-MIF para su uso en el tratamiento de enfermedades inflamatorias | |
| Davies et al. | Clinical experience of IL-6 blockade in rheumatic diseases—implications on IL-6 biology and disease pathogenesis | |
| US9394362B2 (en) | IL-21 antibodies and methods of making or using the antibodies | |
| US6399078B1 (en) | Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases | |
| JP2014519524A (ja) | 抗ｐｓｇｌ−１抗体およびその使用 | |
| US10093727B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| EP2279001B1 (en) | Inhibitors of gm-csf and il-17 for therapy | |
| RU2656162C2 (ru) | Антитела к интерлейкину 6 и их применение | |
| JP2021533204A5 (enExample) | ||
| JP6865826B2 (ja) | インターロイキン１７ａを標的とする抗体、その製造方法及び応用 | |
| TWI691512B (zh) | Ｆｃ融合高親和性ＩｇＥ受體α鏈 | |
| WO2000050088A2 (en) | Biotinylated-chemokine antibody complexes | |
| AU2015275926A1 (en) | Oral composition of anti-TNF alpha antibodies | |
| JP2018502603A (ja) | 新規組換え抗ＴＮＦ−αキメラモノクローナル抗体の製造方法及び用途 | |
| RS57291B1 (sr) | Pan-elr+cxc hemokin antitela | |
| ITMI960358A1 (it) | Citochine modificate per l'uso in terapia | |
| Chopade et al. | Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats | |
| JP2023145581A (ja) | インターロイキン－２３受容体のペプチド阻害剤の組成物 | |
| Duan et al. | A synthetic MD-2 mimetic peptide attenuates lipopolysaccharide-induced inflammatory responses in vivo and in vitro | |
| Al Faruque et al. | Stepwise inhibition of T cell recruitment at post-capillary venules by orally active desulfated heparins in inflammatory arthritis | |
| ITMI20011833A1 (it) | Agenti che regolano la permeabilita' vascolare | |
| JP6578546B2 (ja) | Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬 | |
| CN120118174A (zh) | Ccr4的胞外段重组蛋白及其用途 | |
| Ducreux et al. | The inhibitory potencies of monoclonal antibodies to the macrophage adhesion molecule sialoadhesin are greatly increased following PEGylation |